Federal award
SCHOTT PHARMA USA, INC.
W58P052220003
Assistance
Obligated and Ceiling
- Obligated (net)
- $4,775,756.73
- Potential value
- —
- Current value
- —
- Gross positive obligations
- $42,775,490.77
Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.
Award Details
- Recipient
- SCHOTT PHARMA USA, INC. · P6NCYH5J8BQ3
- Owner company
- Not a reviewed companyNo reviewed company owns this recipient.
- Reported parent
- CARL-ZEISS-STIFTUNG · K71UEB6ER3L8
- Awarding agency
- Department of Defense · sub-agency 2100 · office W58P05
- Funding agency
- Department of Defense · sub-agency 2100
- Assistance listing (CFDA)
- CFDA 12.360
- FAIN
- W58P052220003
- Award type code
- 05
- Actions
- 5 · Jan 21, 2022 to Aug 29, 2023
- Why it is listed
- a program on the reviewed research-assistance allowlist (DoD, DOE or NASA from $10k, or eligible DHS research)
Action History5
| Date | FY | Mod | Action type | Obligation | Company in company totals |
|---|---|---|---|---|---|
| Aug 29, 2023 | FY2023 | P00008 | B1 | −$25,999,734.04 | — |
| May 19, 2023 | FY2023 | P00006 | B1 | −$12,000,000.00 | — |
| Mar 17, 2023 | FY2023 | P00005 | B1 | $284,403.77 | — |
| Feb 14, 2023 | FY2023 | ARZ999 | EX | $0.00 | — |
| Jan 21, 2022 | FY2022 | 0 | A1 | $42,491,087.00 | — |
Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.